Albumin fusion proteins
AssigneeHuman Genome Sciences, Inc.
InventorsCraig A. Rosen, William A. Haseltine, Steven M. Ruben
Life of this patent
Estimating the term…
Abstract
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
Claims9
A method of treating a human comprising administering to said human a therapeutically effective amount of a pharmaceutical composition comprising an albumin fusion protein consisting of two tandemly oriented GLP-1(7-36(A8G)) polypeptides and SEQ ID NO:
- 1038, wherein the C-terminus of said two tandemly oriented GLP-1(7-36(A8G)) polypeptides is fused to the N-terminus of SEQ ID NO:
- 1038, and wherein said human has Type II diabetes.
A method of treating a human comprising administering to said human a pharmaceutical composition comprising an albumin fusion protein produced by a host cell comprising construct ID 3070, which is contained in ATCC deposit No. PTA-4671, and wherein said human has Type II diabetes.
Dependencies are inferred from the claim text.